Trend decks tell you what is selling. They rarely tell you which claims will get your Amazon listing suppressed or your EU notification rejected. This is the version with the compliance layer attached.
August is when Q4 gets decided. If a new SKU is not locked by early September, it will not clear formulation, stability, safety substantiation and first production in time for Black Friday. So let's be practical about the four categories currently dominating private label briefs โ and honest about which ones have real evidence behind them.
1. Cooling beauty: the trend with the best physics and the weakest regulatory risk
Cooling is the rare trend where the mechanism is genuinely well understood and the compliance path is easy.
There are two independent levers, and good 2026 formulas use both:
The important upgrade over first-generation menthol products is that WS-23 (a third-generation synthetic coolant) activates TRPM8 without the trigeminal irritation and characteristic mint smell that made menthol unusable in facial skincare. That single swap is why cooling has escaped the body-spray ghetto and entered creams, masks, serums and even primers.
Claim discipline. Cooling sensation is a straightforward cosmetic claim in the US and EU โ you are describing a sensory attribute. What you cannot do is drift into "reduces inflammation", "treats heat rash" or "lowers body temperature". Those are drug claims under the FD&C Act, and under MoCRA the FDA has considerably more visibility into your product than it did pre-2023. Say feels cooling, soothing sensory experience, refreshing โ and stop there.
Formulation warning. Coolants are volatile and can migrate. Package matters: airless pumps and well-sealed tubes preserve intensity far better than open jars, where sensory strength can noticeably fade over shelf life.
2. PDRN: strong story, real science, wrong dosage form
PDRN (polydeoxyribonucleotide) is derived from salmon DNA and has been used in Korea for over a decade as an injectable skin-repair material. That clinical history is real. The problem is what happens when it moves into a topical serum.
Here is the honest evidence grade:
- Injectable PDRN โ substantial published clinical literature. Not your product.
- Topical PDRN โ limited controlled data. PDRN is a high-molecular-weight polynucleotide, and molecules of that size do not cross an intact stratum corneum efficiently. Delivery is the unsolved formulation problem, not a marketing problem.
So when a topical PDRN serum claims it "rivals injectable results", that is a cross-dosage-form exaggeration and you should treat it as a red flag โ the same way you would treat "7-day whitening".
Does that mean skip it? No. PDRN is an excellent narrative ingredient for a private label brand: credible scientific provenance, aesthetic-clinic association, K-beauty tailwind. It works commercially as long as you hold the cosmetic line โ hydration, soothing, skin texture, barrier support โ and never cross into tissue regeneration or wound healing, which are unambiguously drug claims in both the US and EU.
Two sourcing notes for Western markets:
- Salmon-derived PDRN is animal-origin. It is incompatible with a vegan positioning, and EU brands should confirm supplier documentation on origin and traceability before CPNP notification.
- Plant-derived "PDRN-like" polynucleotide alternatives (commonly marketed as rose PDRN) exist and solve the vegan and clean-beauty problem โ at the cost of even thinner evidence. Be equally disciplined with claims.
3. Peptides: the market moved from "a peptide" to "a peptide system"
Until recently, adding 0.001% of a single peptide and writing "peptide anti-aging" on the carton was enough. Consumers have caught up. The 2026 conversation is about which peptides and why they are combined.
A defensible multi-peptide architecture looks like this:
Three pathways, one coherent story. That is a real differentiator versus a single-peptide competitor.
The barrier to entry is chemistry, not marketing. Peptides have narrow pH windows and genuine incompatibilities:
- Palmitoyl Pentapeptide-4 degrades below roughly pH 4 โ you cannot simply drop it into an acid exfoliant.
- Copper Tripeptide-1 is deactivated by chelators such as EDTA and by strong acids, and copper can discolour a formula. It generally wants its own phase, or its own SKU.
- Peptides and high-percentage direct vitamin C rarely make good roommates.
If a supplier agrees to "just combine all of them" without discussing pH and chelation, that is diagnostic information about the supplier.
4. Body and scalp care: the fastest-moving underserved category
The clearest structural shift of 2026 is that facial-grade actives have migrated south. Consumers who read INCI lists for their serum now read them for their body lotion โ and they are no longer satisfied with a large cheap bottle of occlusive.
What is actually selling:
- Ceramide and barrier body creams โ a straight port of the CeraVe logic to full-body use
- Niacinamide body serums โ texture and tone claims on arms, legs, back
- Exfoliating acid body treatments โ lactic acid and urea for keratosis pilaris positioning
- Scalp serums โ the biggest single opportunity, because "scalp barrier" and "scalp aging" reframe a cleansing category as a treatment category with treatment margins
Scalp is worth emphasising. Shampoo competes on price. A scalp serum competes on efficacy and carries a serum's gross margin. Same customer, same shelf, different economics.
US regulatory note: an anti-dandruff claim moves the product into OTC drug territory (monograph actives such as zinc pyrithione or ketoconazole). Scalp hydration, soothing, barrier support and appearance of density remain cosmetic. Choose your side deliberately, because it changes your entire filing pathway and cost base.
The compliance checklist before you sign a Q4 PO
Whatever category you pick, these are non-negotiable for the US and EU in 2026:
United States (MoCRA):
- Facility registration and product listing with FDA
- A named Responsible Person on the label
- Adequate safety substantiation on file โ not the supplier's marketing deck
- Serious adverse event reporting process in place
- Fragrance allergen labelling as the phase-in schedule tightens
European Union / UK:
- CPNP notification before placing on market (UK SCPN separately)
- EU-based Responsible Person
- Cosmetic Product Safety Report (Parts A and B) signed by a qualified safety assessor
- Full ingredient compliance against Annexes IIโVI of Regulation 1223/2009
Ask your manufacturer for the safety assessment, the stability and compatibility data, and the challenge test โ before the deposit, not after the first complaint.
Realistic timeline and MOQ from a China OEM
MOQ: typically 500โ1,000 units per SKU for stock formulas; bespoke development runs higher. A realistic read: a brief locked in early August can ship as finished goods in late Q4 โ a brief locked in October cannot.
Marketing red flags to avoid in your own copy
Applying the four-question test to this year's trends:
- "Clinically proven PDRN serum" โ ask which dosage form the clinical data used. If it is injectable, the claim is borrowed, not earned.
- "Cools skin by 5ยฐC for 8 hours" โ physical cooling from polyol dissolution is real but transient. A sustained multi-hour temperature-drop number is not credible.
- "Multi-peptide complex" with all peptides below position 12 on the INCI list โ a spoonful of sugar in a whole pot of soup. Present, but not enough to matter.
- "Regenerates skin tissue" โ a drug claim in both the US and EU. This is not aggressive marketing, it is a filing problem.
Choose the trend that fits your existing customer, not the one with the loudest headline. Cooling is the lowest-risk entry, peptides give the strongest differentiation story, body and scalp offer the least crowded shelf, and PDRN buys attention if you can keep your copywriters disciplined.
๐ Ready to lock a Q4 SKU? Send us your category, target price and market and we will come back with a formula direction, MOQ and a dated timeline โ https://www.quickoem.com/en/contact